Navigation Links
Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
Date:10/21/2010

OMAHA, Neb., Oct. 21 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced that Eric Johnson, Ph.D. has joined the company as Medical Director for Laboratory Services.  In this newly created position Dr. Johnson will be responsible for leading the strategic vision and managing the day-to-day operations of Transgenomic's Molecular Diagnostics Services lab.

Dr. Johnson brings to Transgenomic nearly 20 years of genetics experience in both research and diagnostics.  Most recently he served as the founder of the Neurovascular / Epilepsy Genetics Research Laboratory at the Barrow Neurological Institute in Phoenix, Arizona and has helped to establish and mentor BioBanking efforts for a number of rare disease family groups, both independently and as the founding Director of the DNA and Tissue Archive of the Genetic Alliance BioBank.

His experience in the clinic includes being the founding director of the Molecular Diagnostics and BioBanking Laboratories at St. Joseph's Hospital in Phoenix; serving as director of diagnostic testing at Prevention Genetics in Marshfield, Wisc.; and holding the position of Chief Scientific Officer and Clinical Laboratory Director for Iverson Genetic Diagnostics in Seattle, a personalized medicine genetic diagnostics company.

Dr. Johnson has authored and co-authored numerous publications on the nature, identity and function of several epilepsy and neurovascular related genes including FEB2, a febrile seizure susceptibility gene, SCN1B, a Febrile seizure "plus" gene, and CCM1, CCM2 and CCM3, three causative genes for cerebral cavernous malformations. He is considered an expert in translational research: moving tests for heritable diseases from the laboratory bench to the clinic, as evidenced by presenting at more than 50 genetic conferences and workshops during his career.

"Dr. Johnson brings tremendous experience to this position," said Craig Tuttle, Transgenomic President and Chief Executive Officer.  "His expertise in genetic test development, combined with his Neuroscience training, will help us build our market leadership position in our Molecular Diagnostics Services business.  We are excited to have him on board."

Commenting on his appointment, Dr. Johnson said, "I am very excited to be joining Transgenomic at such an important inflection point in the company's development. The promise of personalized medicine is becoming a reality in patient care, and I look forward to working with Transgenomic's powerful technologies, COLD-PCR for example, to support the company's goal of being a leader in genetic mutation detection in cancer and neurological diseases."

Dr. Johnson received a B.A. in biology/chemistry from Boston University and a Ph.D. in Neuropharmacology/Neuroscience from the University of Pennsylvania.  He did post-doctoral work in Psychiatry and Neurosurgery at Yale University, and received advanced training genetics at the Jackson Laboratory in Bar Harbor, Maine.

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, nearly 1,500 systems have been shipped to customers in more than 50 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.


'/>"/>
SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of Euro 24.75 per Ordinary Share of Crucell
2. aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
3. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
4. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
5. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
6. Johnson & Johnson Completes Acquisition of Cougar Biotechnology
7. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
8. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
9. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
10. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
11. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , December 9, 2016 According to ... Services (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, ... to 2021" published by MarketsandMarkets, the global market is expected to ... 2016, at a CAGR of 10.6% during the forecast period. ... ...
(Date:12/8/2016)... Philadelphia, PA (PRWEB) , ... December 08, 2016 ... ... fan engagement platforms, the business of innovation is taking over sports. On Thursday, ... executive will explore how technology is disrupting the playing field at a Smart ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... bioInformatics portal. In response to client demand KbioBox developed a sophisticated “3 click” ... program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ and ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
Breaking Biology News(10 mins):